HK1200831A1 - A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2- - Google Patents

A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2-

Info

Publication number
HK1200831A1
HK1200831A1 HK15101433.6A HK15101433A HK1200831A1 HK 1200831 A1 HK1200831 A1 HK 1200831A1 HK 15101433 A HK15101433 A HK 15101433A HK 1200831 A1 HK1200831 A1 HK 1200831A1
Authority
HK
Hong Kong
Prior art keywords
fluorophenoxy
methylpyridine
aminocarbonyl
carboxamide
monohydrate
Prior art date
Application number
HK15101433.6A
Other languages
English (en)
Chinese (zh)
Inventor
Juergen Stiehl
Werner Heilmann
Michael Lgers
Joachim Rehse
Michael Gottfried
Saskia Wichmann
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1200831(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1200831A1 publication Critical patent/HK1200831A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
HK15101433.6A 2010-04-15 2015-02-10 A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2- HK1200831A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15

Publications (1)

Publication Number Publication Date
HK1200831A1 true HK1200831A1 (en) 2015-08-14

Family

ID=44070712

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101433.6A HK1200831A1 (en) 2010-04-15 2015-02-10 A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2-

Country Status (39)

Country Link
US (5) US8748622B2 (es)
EP (1) EP2558448B1 (es)
JP (1) JP5934182B2 (es)
KR (2) KR101800041B1 (es)
CN (2) CN102947271B (es)
AR (2) AR081060A1 (es)
AU (1) AU2011240113B2 (es)
BR (1) BR112012026117B1 (es)
CA (1) CA2796238C (es)
CL (1) CL2012002840A1 (es)
CO (1) CO6630136A2 (es)
CR (1) CR20120526A (es)
CU (2) CU24123B1 (es)
DK (1) DK2558448T3 (es)
DO (2) DOP2012000268A (es)
EC (1) ECSP12012234A (es)
ES (1) ES2542610T3 (es)
GT (1) GT201200280A (es)
HK (1) HK1200831A1 (es)
HR (1) HRP20150885T1 (es)
HU (1) HUE026821T2 (es)
IL (2) IL222348B (es)
JO (1) JO3158B1 (es)
MA (1) MA34156B1 (es)
MX (1) MX2012011734A (es)
MY (2) MY162359A (es)
NZ (1) NZ602997A (es)
PE (2) PE20160838A1 (es)
PL (1) PL2558448T3 (es)
PT (1) PT2558448E (es)
RS (1) RS54219B1 (es)
RU (1) RU2581585C2 (es)
SG (2) SG184172A1 (es)
SI (1) SI2558448T1 (es)
TN (1) TN2012000492A1 (es)
TW (2) TWI539951B (es)
UA (1) UA110613C2 (es)
UY (2) UY33290A (es)
WO (1) WO2011128261A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877933B2 (en) * 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
EP1868579B1 (en) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
EA032023B1 (ru) 2012-09-25 2019-03-29 Байер Фарма Акциенгезельшафт Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
IN2013CH04511A (es) 2013-10-04 2015-04-10 Hetero Research Foundation
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
US20190300484A1 (en) * 2016-01-18 2019-10-03 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
DK3630112T3 (da) 2017-06-02 2024-04-22 Bayer Healthcare Llc Kombination af regorafenib og nivolumab til behandling af cancer
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
PT1450799E (pt) 2001-12-03 2007-01-31 Bayer Pharmaceuticals Corp Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
CA2475818C (en) 2002-02-11 2011-07-19 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US8796250B2 (en) 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
BR122016015715B8 (pt) * 2003-07-23 2021-05-25 Bayer Healthcare Llc composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico
EP1751139B1 (en) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2007002398A (es) 2004-08-27 2007-05-15 Bayer Pharmaceuticals Corp Nuevas composiciones farmaceuticas para el tratamiento de cancer.
US8877933B2 (en) 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
SI1797037T1 (sl) 2004-09-29 2015-06-30 Bayer Healthcare Llc Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida
EP1868579B1 (en) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
JP2009515978A (ja) 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100063112A1 (en) * 2006-11-09 2010-03-11 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
CA2673041A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
WO2008089389A2 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
EP2114403A2 (en) 2007-01-19 2009-11-11 Bayer Healthcare, LLC Treatment of cancers having resistance to chemotherapeutic agents
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
JP5439494B2 (ja) 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
MX2011012201A (es) 2009-05-15 2011-12-08 Novartis Ag Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
BR112013033831A2 (pt) 2011-06-28 2017-02-14 Bayer Healthcare Llc composição farmacêutica oftalmológica tópica que contém regorafenib
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Also Published As

Publication number Publication date
AR081060A1 (es) 2012-06-06
RU2012148386A (ru) 2014-05-20
IL253119B (en) 2018-03-29
GT201200280A (es) 2014-07-23
DOP2012000268A (es) 2012-12-15
AU2011240113A1 (en) 2012-10-11
MY162359A (en) 2017-06-15
CA2796238A1 (en) 2011-10-20
UY39590A (es) 2022-01-31
US9458107B2 (en) 2016-10-04
PE20160838A1 (es) 2016-09-24
PE20130181A1 (es) 2013-02-23
SG184172A1 (en) 2012-11-29
US20170334857A1 (en) 2017-11-23
MY177066A (en) 2020-09-03
RU2581585C2 (ru) 2016-04-20
ECSP12012234A (es) 2012-11-30
EP2558448B1 (en) 2015-05-20
SG10201501221UA (en) 2015-04-29
US20170057918A1 (en) 2017-03-02
JO3158B1 (ar) 2017-09-20
CN102947271A (zh) 2013-02-27
CR20120526A (es) 2013-03-11
SI2558448T1 (sl) 2015-11-30
CU20120147A7 (es) 2013-01-30
MA34156B1 (fr) 2013-04-03
BR112012026117B1 (pt) 2022-08-30
US20140221661A1 (en) 2014-08-07
US20190144391A1 (en) 2019-05-16
TW201509415A (zh) 2015-03-16
CU24123B1 (es) 2015-08-27
DOP2016000285A (es) 2016-11-30
NZ602997A (en) 2014-10-31
IL222348B (en) 2018-08-30
ES2542610T3 (es) 2015-08-07
RS54219B1 (en) 2015-12-31
KR20130061670A (ko) 2013-06-11
IL253119A0 (en) 2017-08-31
US10822305B2 (en) 2020-11-03
PT2558448E (pt) 2015-09-01
AR116395A2 (es) 2021-05-05
CN102947271B (zh) 2016-11-09
CL2012002840A1 (es) 2013-01-18
KR20170129276A (ko) 2017-11-24
JP2013523851A (ja) 2013-06-17
BR112012026117A8 (pt) 2017-12-19
TWI475992B (zh) 2015-03-11
UA110613C2 (uk) 2016-01-25
IL222348A0 (en) 2012-12-31
DK2558448T3 (en) 2015-08-24
KR101800041B1 (ko) 2017-11-21
MX2012011734A (es) 2012-12-17
UY33290A (es) 2011-12-01
US8748622B2 (en) 2014-06-10
JP5934182B2 (ja) 2016-06-15
TWI539951B (zh) 2016-07-01
EP2558448A1 (en) 2013-02-20
TN2012000492A1 (en) 2014-04-01
CA2796238C (en) 2019-12-31
AU2011240113B2 (en) 2014-12-18
TW201204356A (en) 2012-02-01
CN103980191A (zh) 2014-08-13
HRP20150885T1 (hr) 2015-10-09
CO6630136A2 (es) 2013-03-01
BR112012026117A2 (pt) 2015-09-08
WO2011128261A1 (en) 2011-10-20
CU20140060A7 (es) 2014-10-02
PL2558448T3 (pl) 2015-10-30
US20130116442A1 (en) 2013-05-09
HUE026821T2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
HK1200831A1 (en) A process for preparing 4-4-[([4-chloro-3-(trifluoromethyl) phenyl]aminocarbonyl)amino]-3-fluorophenoxy-n-methylpyridine-2- carboxamide, its salts and monohydrate 4-4-[([4--3-()])]-3--n- -2-
HK1206261A1 (en) Alpha amino boronic acid derivatives, selective immunoproteasome inhibitors
HK1198822A1 (en) Method for producing a toothbrush, and toothbrush
PL2524658T3 (pl) Ulepszona konfiguracja wyrównania kowadełka i wkładu dla staplera okrężnego
PT2489670T (pt) Processo para a preparação de compostos de quelatos de aminoácidos, compostos de quelatos de aminoácidos e utilização de compostos de quelatos de aminoácidos
BRPI1014760A8 (pt) preparação compreendendo insulina, nicotinamida e um aminoácido
IL225832A0 (en) A method for the preparation of modified isoxazoline compounds and their starting materials 4-chloro, 4-bromo or 4-iodo-benzaldehyde oximes
EP2562152A4 (en) PROCESS FOR PREPARING 2,5-DIMETHYLPHENYL-ACETIC ACID
EP2795048A4 (en) WELL COMPLETION ARRANGEMENT AND METHOD FOR PREPARING A WELL FOR ABANDONMENT
HK1177211A1 (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
EP2725010A4 (en) AMID CONNECTION, MANUFACTURING METHOD AND USE
SI2598479T1 (sl) Postopek za pripravo ramiprila
PT2683361E (pt) Método para a preparação de uma solução de levotiroxina
IL226336A0 (en) A preparation containing insulin, nicotinamide and amino acid
HRP20130368T1 (en) New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid
EP2684953A4 (en) MODIFIED AMINO TRANSFERASE, GENE AND METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE AMINO BINDING THEREWITH
PL2793559T3 (pl) Wkład oraz kubek udojowy
PL2607353T3 (pl) Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem farmaceutycznie dopuszczalnym
EP2669275A4 (en) CAPSULE COMPOUND, ANION REMOVAL AGENT, AND ANION REMOVAL METHOD
ZA201401262B (en) Pures-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1h,-5h-benzo[i,j]quinolizine-2- carboxylic acid l-arginine salt tetrahydrate and a process for its preparation
PL393501A1 (pl) Nowe sole jodoniowe, sposób ich wytwarzania i zastosowanie oraz nowy związek wyjściowy do wytwarzania nowych soli jodoniowych, sposób jego wytwarzania i zastosowanie
EP2699560A4 (en) 5-CARBAMOYL-ADAMANTAN-2-YL AMID DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS AND METHOD FOR THE PRODUCTION THEREOF
HU1000498D0 (en) New salts and preparation process thereof
GB201116665D0 (en) Process for preparing a particulate solid and a particulate solid